Tests an AI tool that reads kidney biopsy images for glomerulonephritis
Compares an AI kidney biopsy reader with pathologists in people with glomerulonephritis.
Plain-language title generated from the registry record
Registry title: The Clinical Application of Artificial Intelligence Assisted Renal Biopsy Diagnosis System.
Key facts
- Where
- Guangzhou, ChinaSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 15 and 79 years old?
Source: NCT07330362, who can take part
Where in China
- Nanfang HospitalGuangzhou, ChinaTaking people
- Zhujiang Hospital of Southern Medical UniversityGuangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Zhujiang Hospital
- Trial code
- NCT07330362
- Record updated
- 27 January 2026
- Original description
This research project aims to collect images from patients with chronic glomerulonephritis. For each subject, the images obtained from renal biopsy will undergo evaluation by both the diagnostic model and the 'gold standard' diagnosis by pathologists. The researchers will test the subjects using the diagnostic model and compare the results with the known 'gold standard' diagnosis, in order to evaluate the AUC, specificity, and sensitivity of the diagnostic model.Read full original descriptionShow less
The Clinical Application of Artificial Intelligence Assisted Renal Biopsy Image Diagnosis System.
This research project aims to collect images from patients with chronic glomerulonephritis. For each subject, the images obtained from renal biopsy will undergo evaluation by both the diagnostic model and the 'gold standard' diagnosis by pathologists. The researchers will test the subjects using the diagnostic model and compare the results with the known 'gold standard' diagnosis, in order to evaluate the AUC, specificity, and sensitivity of the diagnostic model.
Inclusion: Voluntary signing of informed consent form; Patients clinically diagnosed or suspected of having chronic kidney disease according to the 2023 KDIGO Clinical Practice Guideline for the Evaluation and Management of Kidney Disease; Undergoing renal biopsy and pathological specimen preparation.
Exclusion: Biopsy tissue from donor kidney or transplanted kidney; Poor quality of pathological specimen, unable to conduct pathological diagnosis.